Tessa Romero
Stock Analyst at J.P. Morgan
(4.69)
# 802
Out of 4,644 analysts
196
Total ratings
57.4%
Success rate
22.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Rated: Buy | $97 → $103 | $75.45 | +36.51% | 33 | Aug 13, 2026 | |
| SRRK Scholar Rock Holding | Rated: Buy | $56 → $63 | $54.72 | +15.13% | 10 | Aug 13, 2026 | |
| XENE Xenon Pharmaceuticals | Maintained: Buy | $82 | $64.49 | +27.16% | 16 | Aug 11, 2026 | |
| DYN Dyne Therapeutics | Reiterated: Hold | n/a | $26.23 | - | 14 | Jul 30, 2026 | |
| EYPT EyePoint | Maintained: Buy | $33 → $30 | $13.52 | +121.89% | 7 | Jul 22, 2026 | |
| BHVN Biohaven | Maintained: Buy | n/a | $14.45 | - | 14 | Jun 30, 2026 | |
| LRMR Larimar Therapeutics | Reiterated: Buy | $9 | $4.26 | +111.27% | 2 | Jun 29, 2026 | |
| LXEO Lexeo Therapeutics | Maintained: Buy | $9 | $4.85 | +85.57% | 4 | Jun 25, 2026 | |
| UPB Upstream Bio | Downgraded: Hold | $8 | $6.94 | +15.36% | 10 | Jun 12, 2026 | |
| AGIO Agios Pharmaceuticals | Rated: Hold | $31 | $33.99 | -8.80% | 17 | Jun 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $27.07 | - | 3 | Jun 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 | $24.46 | +71.71% | 2 | Jun 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $45 → $53 | $43.56 | +21.67% | 21 | Jun 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $23 | $13.05 | +76.25% | 4 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | n/a | $1.72 | - | 5 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | n/a | $3.37 | - | 2 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $38 | $46.26 | -17.86% | 3 | Mar 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $31 → $34 | $29.13 | +16.72% | 19 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.18 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $4.47 | n/a | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.69 | n/a | 4 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $22 → $10 | $8.85 | n/a | 2 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $40.98 | n/a | 1 | Nov 9, 2020 |
Cytokinetics
Aug 13, 2026
Rated: Buy
Price Target: $97 → $103
Current: $75.45
Upside: +36.51%
Scholar Rock Holding
Aug 13, 2026
Rated: Buy
Price Target: $56 → $63
Current: $54.72
Upside: +15.13%
Xenon Pharmaceuticals
Aug 11, 2026
Maintained: Buy
Price Target: $82
Current: $64.49
Upside: +27.16%
Dyne Therapeutics
Jul 30, 2026
Reiterated: Hold
Price Target: n/a
Current: $26.23
Upside: -
EyePoint
Jul 22, 2026
Maintained: Buy
Price Target: $33 → $30
Current: $13.52
Upside: +121.89%
Biohaven
Jun 30, 2026
Maintained: Buy
Price Target: n/a
Current: $14.45
Upside: -
Larimar Therapeutics
Jun 29, 2026
Reiterated: Buy
Price Target: $9
Current: $4.26
Upside: +111.27%
Lexeo Therapeutics
Jun 25, 2026
Maintained: Buy
Price Target: $9
Current: $4.85
Upside: +85.57%
Upstream Bio
Jun 12, 2026
Downgraded: Hold
Price Target: $8
Current: $6.94
Upside: +15.36%
Agios Pharmaceuticals
Jun 11, 2026
Rated: Hold
Price Target: $31
Current: $33.99
Upside: -8.80%
Jun 11, 2026
Maintained: Buy
Price Target: n/a
Current: $27.07
Upside: -
Jun 8, 2026
Reiterated: Buy
Price Target: $42
Current: $24.46
Upside: +71.71%
Jun 5, 2026
Rated: Buy
Price Target: $45 → $53
Current: $43.56
Upside: +21.67%
Jun 3, 2026
Maintained: Buy
Price Target: $23
Current: $13.05
Upside: +76.25%
May 26, 2026
Maintained: Sell
Price Target: n/a
Current: $1.72
Upside: -
Apr 2, 2026
Maintained: Sell
Price Target: n/a
Current: $3.37
Upside: -
Mar 24, 2026
Rated: Buy
Price Target: $38
Current: $46.26
Upside: -17.86%
Mar 4, 2026
Rated: Buy
Price Target: $31 → $34
Current: $29.13
Upside: +16.72%
Nov 18, 2025
Maintained: Hold
Price Target: n/a
Current: $3.18
Upside: -
Oct 23, 2024
Downgraded: Sell
Price Target: n/a
Current: $4.47
Upside: n/a
Oct 18, 2024
Maintained: Hold
Price Target: n/a
Current: $3.69
Upside: n/a
Jul 13, 2022
Downgraded: Hold
Price Target: $22 → $10
Current: $8.85
Upside: n/a
Nov 9, 2020
Downgraded: Hold
Price Target: n/a
Current: $40.98
Upside: n/a